AMBU B Ambu A/S Class B

Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities

Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities

Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.  

The attached document discloses the data of the transactions made in Ambu shares. 

Attachment



EN
09/02/2024

Underlying

AMBU BAmbu A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
AMBU B Ambu A/S Class ...

Ambu (Buy, TP: DKK165.00) - Solid underlying momentum

Ambu pre-released headline Q1 figures and raised its full-year guidance recently, so focus with the detailed results was on the growth split within the important endoscopy business, with concerns related to the strong pulmonology growth being affected by favourable order timing and slowing Ex-pulmonology growth. We have trimmed estimates but find the case unchanged. We reiterate our BUY and DKK165 target price.

AMBU B AMBU A/S CLASS B
01/31/25 January 31, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
AMBU B AMBU A/S CLASS B
01/31/25 January 31, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
AMBU B Ambu A/S Class ...

Ambu (Buy, TP: DKK165.00) - Strong scope for growth

Following the significant preliminary Q1 results beat, we believe momentum is building and see further upside potential to the 2024/25 outlook, but also beyond after our deep dive into Ambu’s growth levers. Following physician feedback, we are particularly optimistic on the recent launch of Ambu’s new single-use ureteroscope. We find it increasingly likely the company meets its c20% EBIT margin target at least one year ahead of schedule. We reiterate our BUY and have raised our target price to D...

AMBU B AMBU A/S CLASS B
01/22/25 January 22, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
AMBU B AMBU A/S CLASS B
01/13/25 January 13, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
AMBU B AMBU A/S CLASS B
01/10/25 January 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch